Download App

Log in to access Online Inquiry
Company Overview More
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > RANI Rani Therapeutics > Detailed Quotes

RANI Rani Therapeutics

10.770-0.120-1.10%
Close 05/26 20:00 ET
High
11.270
Open
10.710
Turnover
159.29K
Low
10.440
Pre Close
10.890
Volume
14.70K
Market Cap
529.46M
P/E(TTM)
Loss
52wk High
36.270
Shares
49.16M
P/E(Static)
Loss
52wk Low
9.240
Float Cap
109.22M
Bid/Ask %
0.00%
Historical High
36.270
Shs Float
10.14M
Volume Ratio
0.47
Historical Low
9.240
Dividend TTM
--
Div Yield TTM
--
P/B
9.92
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.14%
Amplitude
7.62%
Avg Price
10.836
Lot Size
1
Float Cap
109.22M
Bid/Ask %
0.00%
Historical High
36.270
Shs Float
10.14M
Volume Ratio
0.47
Historical Low
9.240
Dividend TTM
--
P/B
9.92
Dividend LFY
--
Turnover Ratio
0.14%
Amplitude
7.62%
Avg Price
10.836
Lot Size
1
Price Forecast

No Data

News

Comment